105076-76-4

Basic information

• Product Name: N-(4-AMINOPHENYL)-2-MORPHOLIN-4-YLACETAMIDE
• Synonyms: N-(4-AMINOPHENYL)-2-MORPHOLIN-4-YLACETAMIDE;N-(4-aminophenyl)-2-morpholin-4-ylacetamide(SALTDATA: FREE);N-(4-aminophenyl)-4-morpholineacetamide;N-(4-aminophenyl)-2-morpholinoacetamide
• CAS NO: 105076-76-4
• Molecular Formula: C₁₂H₁₇N₃O₂
• Molecular Weight: 235.28
• Mol File: 105076-76-4.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 384.513°C at 760 mmHg
• Flash Point: 186.347°C
• Appearance: /
• Density: 1.242g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.618
• CAS DataBase Reference: N-(4-AMINOPHENYL)-2-MORPHOLIN-4-YLACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-AMINOPHENYL)-2-MORPHOLIN-4-YLACETAMIDE(105076-76-4)
• EPA Substance Registry System: N-(4-AMINOPHENYL)-2-MORPHOLIN-4-YLACETAMIDE(105076-76-4)

Safety Data

• Hazardous Substances Data: 105076-76-4(Hazardous Substances Data)

Usage

General Description

N-(4-aminophenyl)-2-morpholin-4-ylacetamide is a chemical compound with the molecular formula C13H18N4O2. It is a synthetic intermediate used in the production of pharmaceuticals, particularly in the development of potential drugs targeting various biological processes. The compound contains a morpholine ring and an amino group, making it a versatile building block for the synthesis of small molecule inhibitors and other bioactive compounds. Its unique structure and properties make it a valuable tool for chemical synthesis and drug discovery processes, with potential applications in the development of new medications for various medical conditions.

InChI:InChI=1/C12H17N3O2/c13-10-1-3-11(4-2-10)14-12(16)9-15-5-7-17-8-6-15/h1-4H,5-9,13H2,(H,14,16)

Upstream product

• 110-91-8 morpholine 
• 3598-91-2 N-(4-nitrophenyl)bromoacetamide 
• 17329-87-2 2-chloro-N-(4-nitro-phenyl)-acetamide 
• 100-01-6 4-nitro-aniline 
• 262368-13-8 2-morpholin-4-yl-N-(4-nitro-phenyl)-acetamide 

Downstream Products

• 1049677-32-8 8-chloro-3-iodoimidazo[1,2-a]pyrazine 
• 1622093-56-4 N-(4-(4-((4-(1H-phenanthro[9,10-d]imidazol-2-yl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)phenyl)-2-morpholinoacetamide 
• 1446421-13-1 N-(4-(3-(4-(bis(2-chloroethyl)amino)phenyl)ureido)phenyl)-2-morpholinoacetamide 
• 1452128-62-9 4-(4-(2-morpholinoacetamido)anilino)quinazoline 
• 921201-86-7 N-(4-azido-phenyl)-2-(morpholin-4-yl)-acetamide 

Relevant articles and documents

Novel Pyrimidines as Multitarget Protein Tyrosine Kinase Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

A new class of pyrimidine derivatives were identified as potent protein tyrosine kinase (PTK) inhibitors for the treatment of idiopathic pulmonary fibrosis (IPF). Most of these small-molecule inhibitors displayed strong enzymatic activity against BTK and JAK3 kinases at concentrations lower than 10 nM. The representative compound N-(3-((5-chloro-2-(4-((1-morpholino)acetylamino)phenylamino)-4-pyrimidinyl)amino)phenyl)acrylamide (6 a) also exhibited high inhibitory potency toward both BTK and JAK kinase families, as well as ErbB4, at a concentration of 10 nM, achieving rates of inhibition higher than 57 %. Additionally, in vivo biological evaluations showed that 6 a can remarkably decrease the severity of IPF disease. All these investigations suggested that the multi-PTK inhibitor 6 a may serve as a promising agent for the treatment of IPF.

NOVEL IMIDAZO-PYRAZINE DERIVATIVES

The invention provides novel imidazo-pyrazine derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X, m, n, and R1to R3 are as described herein: formula (I). Further provided are pharmace

Design and synthesis of diphenylpyrimidine derivatives (DPPYs) as potential dual EGFR T790M and FAK inhibitors against a diverse range of cancer cell lines

A new class of pyrimidine derivatives were designed and synthesized as potential dual FAK and EGFRT790M inhibitors using a fragment-based drug design strategy. This effort led to the identification of the two most active inhibitors, namely 9a and 9f, against both FAK (IC50 = 1.03 and 3.05 nM, respectively) and EGFRT790M (IC50 = 3.89 and 7.13 nM, respectively) kinase activity. Moreover, most of these compounds also exhibited strong antiproliferative activity against the three evaluated FAK-overexpressing pancreatic cancer (PC) cells (AsPC-1, BxPC-3, Panc-1) and two drug-resistant cancer cell lines (breast cancer MCF-7/adr cells and lung cancer H1975 cells) at concentrations lower than 6.936 μM. In addition, 9a was also effective in the in vivo assessment conducted in a FAK-driven human AsPC-1 cell xenograft mouse model. Overall, this study offers a new insight into the treatment of hard to treat cancers.